Francis Medical's Vanquish System Debuts in Chicago for Prostate Cancer Treatment
Event summary
- University of Chicago urologist Dr. Abhinav Sidana performed the first commercial Vanquish Water Vapor Ablation procedure in Illinois on May 28, 2026.
- The procedure, developed by Francis Medical, received FDA 510(k) clearance in late 2025 and targets localized prostate cancer with minimal invasion.
- Six-month biopsy data from the VAPOR 2 study showed 91% elimination of targeted disease in 110 patients with no device-related serious adverse events.
- Dr. Sidana, a VAPOR 2 clinical investigator, brings the technology to Chicago after positive patient-reported outcomes and satisfaction rates.
The big picture
Francis Medical's commercial debut of the Vanquish System in Chicago represents a strategic milestone in expanding access to minimally invasive prostate cancer treatments. The procedure's positive clinical trial results and FDA clearance position it as a potential disruptor in the urology sector, particularly as demand grows for treatments that preserve quality of life. The technology's success could accelerate adoption of thermal ablation techniques in other cancer treatments.
What we're watching
- Adoption Pace
- How quickly other major medical centers will integrate the Vanquish System into their prostate care pathways.
- Regulatory Clarity
- Whether the FDA will expand the Vanquish System's indications beyond thermal ablation to include disease treatment claims.
- Competitive Response
- How existing prostate treatment providers will react to this minimally invasive alternative entering the market.
Related topics